Crizotinib was the first approved tyrosine kinase inhibitor (TKI), which led to remarkable responses in patients with advanced ALK + NSCLC compared to standard chemotherapy [2, 3]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.